Pinealon
A short tripeptide studied for neuroprotective and cognitive-enhancing properties, part of the Khavinson peptide bioregulator family.
What is Pinealon?
Pinealon is a tripeptide (Glu-Asp-Arg) developed by Vladimir Khavinson as part of his peptide bioregulator research. It is designed to target pineal gland and brain function, potentially supporting melatonin production, neuroprotection, and cognitive performance. As a short peptide, it can be taken orally and may cross the blood-brain barrier.
What Pinealon Is Investigated For
Pinealon is a Khavinson tripeptide (Glu-Asp-Arg) marketed for cognitive enhancement and mental clarity, neuroprotection, melatonin/pineal-axis support, and general anti-aging brain function. The preclinical support — rat hypoxia-protection studies, cell-viability protection from oxidative stress, and a small Russian clinical trial in truck drivers reporting reduced neurotic disorders — is concentrated essentially entirely within the Khavinson research program and has not been independently replicated by Western laboratories under modern trial-methodology standards. The proposed mechanism of direct DNA-regulatory-region interaction by a tripeptide is contested in Western literature, oral bioavailability of intact short peptides has not been pharmacokinetically confirmed, and no blinded randomized controlled trials exist in humans for any cognitive or longevity endpoint. Russian dietary-complex registration is not equivalent to Western drug approval. Claims of cognitive enhancement, neuroprotection, and longevity exceed what the single-program evidence can independently support — treat it as a theoretical bioregulator, not an established nootropic.
History & Discovery
Pinealon emerged from Vladimir Khavinson's bioregulator program at the St. Petersburg Institute of Bioregulation and Gerontology in the 1990s and 2000s, as part of a deliberate strategy to identify minimal-length active sequences from larger tissue-derived peptide preparations. Where Epithalon (Ala-Glu-Asp-Gly) was the group's pineal tetrapeptide, Pinealon (Glu-Asp-Arg) represents a separate tripeptide claimed to target neuronal and pineal-axis tissue with comparable or distinct effects. The amino acid sequence is short enough that the Khavinson group proposes direct cell-membrane penetration and DNA-regulatory-region interaction as the primary mechanism — a mechanistic claim that is contested in Western literature. The published preclinical and clinical record for Pinealon is concentrated almost entirely within the Khavinson research program and a small set of Russian clinical collaborators. Studies report neuroprotection in rat hypoxia models, cell-viability protection from oxidative stress, and a small clinical trial in Russian truck drivers reporting reduced neurotic disorders. Independent Western replication of these findings is essentially absent, and the broader scientific community has not converged on the mechanistic framework that the Khavinson group proposes for short-peptide gene regulation.
How It Works
Pinealon is believed to support brain health by influencing gene expression in brain cells. As a tiny peptide, it can reach the brain and may help protect neurons and support the pineal gland's production of melatonin.
Pinealon (Glu-Asp-Arg) is proposed to penetrate cells and interact with DNA, modulating gene expression related to neuronal survival and differentiation. Studies suggest it can upregulate anti-apoptotic genes and neurotrophic factors in brain tissue. It may also influence pinealocyte function and melatonin synthesis through epigenetic mechanisms.
Evidence Snapshot
Human Clinical Evidence
Limited. Small clinical studies primarily from Russian institutions show cognitive improvements in elderly patients.
Animal / Preclinical
Moderate. Cell culture and animal studies demonstrate neuroprotective effects.
Mechanistic Rationale
Moderate. Gene regulation by short peptides is an active area of research with some supporting evidence.
Research Gaps & Open Questions
What the current literature has not yet settled about Pinealon:
- 01Independent replication outside the Khavinson research program — neuroprotection, cell-viability, and clinical findings have not been reproduced by Western laboratories under modern trial-methodology standards.
- 02Blinded randomized controlled trials in humans for cognitive enhancement, neuroprotection, or any longevity endpoint.
- 03Pharmacokinetics in humans — absorption (particularly oral and sublingual bioavailability of the intact peptide), distribution, blood-brain-barrier penetration, and clearance have not been characterized.
- 04Mechanism specificity — the proposed mechanism of direct DNA-regulatory-region interaction by a tripeptide is contested in Western literature and has not been independently confirmed.
- 05Long-term safety with cumulative repeated courses, including any effects on neurogenesis-related malignancy risk.
- 06Theoretical cancer-promotion concern — agents that stimulate cell proliferation or modulate gene expression in CNS tissue raise class concerns for tumor-promotion risk in patients with subclinical or remote-history CNS malignancy that have not been adequately addressed.
Forms & Administration
Pinealon is available as oral capsules or sublingual tablets. Treatment courses are typically 10-30 days and may be repeated periodically.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Forum and vendor protocols typically describe 100–200 mcg per dose for injectable forms. Capsule and sublingual products from Russian Khavinson-affiliated manufacturers typically deliver low milligram-range doses formulated for slow release through mucosal absorption. There is no published independent dose-finding study.
Frequency
Daily administration across a short course — typically morning dosing for injectable forms, or 1–2 capsules daily for oral forms.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
10–30 day courses are the standard Khavinson protocol, repeated every 3–6 months — a characteristic feature of Khavinson bioregulator schedules.
Protocol Notes
Injectable research-chemical Pinealon is supplied as lyophilized powder requiring reconstitution in bacteriostatic water; subcutaneous injection is the most commonly described route. Russian Khavinson-affiliated capsule and sublingual products are sold as dietary peptide complexes rather than registered pharmaceuticals. Western clinicians do not generally prescribe it; protocols outside Russia rely on convention and forum consensus rather than anchored clinical guidance. Bioavailability of any oral short peptide is uncertain — the Khavinson group's claims of intact-peptide absorption from oral or sublingual routes have not been confirmed by independent pharmacokinetic study.
Claims for cognitive enhancement, neuroprotection, and longevity exceed what the evidence base, dominated by single-program research, can independently support. Not FDA-approved. Russian protocols come from a single-lab tradition not validated by Western-standard trials. Research-chemical injectable supply is not authorized for human use, and Russian dietary-complex products are not equivalent to approved Western medicines.
Timeline of Effects
Onset
Not characterized in controlled studies. Russian clinical reports describe cognitive parameter changes within the duration of a 10–20 day course. Subjective effects on alertness or sleep, when reported by users, are typically described within the first week of a course.
Peak Effect
Khavinson protocols measure outcomes at the end of a 10–30 day course and at follow-up. There is no characterized peak curve from controlled studies; users typically infer it from convention.
After Discontinuation
No documented withdrawal or rebound. Subjective effects, when reported, fade over weeks of cessation, which is the rationale for the periodic-repeat-course schedule. Long-term cumulative effects from repeated courses across years have not been independently studied.
Common Questions
Who Pinealon Is NOT For
- •Pregnancy — no adequate reproductive toxicology data; not recommended.
- •Breastfeeding — no data on transfer or infant effects.
- •Active or recent-history central nervous system malignancy — neurogenesis-stimulating agents are theoretically concerning in CNS tumor contexts and warrant oncology clinician evaluation.
- •Active seizure disorder — neuromodulatory short peptides have not been adequately studied for seizure-threshold effects; caution warranted.
- •Pediatric use — no safety or developmental data; not recommended.
- •Known hypersensitivity to peptide preparations or to excipients. Research-chemical supply quality and unknown sterility raise injection-site infection risk absent from clinic-supplied medication.
Drug & Supplement Interactions
Documented clinical drug interactions for Pinealon are essentially absent; no formal interaction studies meeting Western standards have been published. Theoretical class concerns include: concurrent use with serotonergic medications, MAOIs, or other psychotropics has not been studied and could plausibly alter neurotransmitter handling given the proposed neuromodulatory mechanism. Concurrent use with anticonvulsants is unstudied. Combination with other Khavinson bioregulators in longevity stacks is common in forum culture but has not been formally evaluated for interaction safety. Patients on any regular medication, particularly psychiatric, neurological, or oncology-related treatments, should disclose Pinealon use to their prescribing clinician.
Safety Profile
Common Side Effects
Cautions
- • Limited Western clinical data
- • Not FDA-approved
- • Most research from Russian institutions
What We Don't Know
Western validation of Khavinson's peptide bioregulator research is limited. Independent replication of results is needed.
Legal Status
United States
Not FDA-approved for any indication. Not recognized as a dietary supplement ingredient. Not on the FDA's list of peptides eligible for 503A compounding. Injectable forms sold primarily through research-chemical suppliers not authorized for human use. Capsule forms from Russian Khavinson-affiliated brands are sometimes imported informally; legitimate clinical access pathways are essentially absent.
International
Russian Khavinson-affiliated capsule and sublingual products are marketed as dietary peptide complexes (not pharmaceuticals) under the Peptides.ru and similar brands. Limited availability through informal CIS distribution. Not approved by EMA, MHRA, Health Canada, or TGA.
Sports & Competition
Not specifically named on the WADA Prohibited List. As an unapproved substance for therapeutic use in most WADA-code jurisdictions, the WADA S0 catch-all category likely applies to injectable forms. Athletes subject to WADA code should treat it as prohibited.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Independent research has confirmed Pinealon's neuroprotective and cognitive effects.
Reality
Very little. Nearly all efficacy data traces to the Khavinson research program and a small set of Russian clinical collaborators. Western laboratories have not independently replicated the core findings under modern trial-methodology standards.
Myth
Because Pinealon is small enough to take orally, it is well-absorbed and reaches the brain intact.
Reality
Oral bioavailability of intact short peptides is uncertain in general, and Pinealon-specific human pharmacokinetic data — including blood-brain-barrier penetration of intact peptide — has not been published in independent studies. The Khavinson group's claim of intact absorption is not anchored to Western-standard pharmacokinetic confirmation.
Myth
Russian dietary-complex registration means Pinealon is approved as a medicine.
Reality
Russian Khavinson-affiliated capsule products are marketed as dietary peptide complexes, not as registered pharmaceuticals. This is a different regulatory category with lower evidence requirements than prescription-medicine approval, and it is not equivalent to approval by EMA, FDA, MHRA, or other Western regulatory bodies.
Myth
Vladimir Khavinson won the Nobel Prize for peptide bioregulator research.
Reality
He did not. Persistent online attributions are inaccurate. The Khavinson group has published extensively, but the body of work has not been recognized at that level by the broader scientific community, and core program claims have not been independently replicated.
Myth
A tripeptide is too small to have meaningful biological effect, so Pinealon is essentially placebo.
Reality
This is the opposite extreme of the previous myth and also wrong. Short peptides can have real biological activity — the question is not whether such activity is theoretically possible but whether the specific claims for Pinealon's mechanism and effect sizes are supported by independent evidence. The honest answer is that Pinealon may have effects, but the existing evidence does not establish them at a Western trial-methodology standard.
Published Research
8 studiesEDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer’s Disease
Role of Mono- and Divalent Ions in Peptide Glu-Asp-Arg-DNA Interaction
[Pinealon and Cortexin influence on behavior and neurochemical processes in 18-month aged rats within hypoxia and hypothermia]
[Regulation of content of cytokines in blood serum and of caspase-3 activity in brains of old rats in model of sharp hypoxic hypoxia with Cortexin and Pinealon]
[The peptide correction of neurotic disorders among professional truck-drivers]
Pinealon protects the rat offspring from prenatal hyperhomocysteinemia
Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes
Regulatory peptides protect brain neurons from hypoxia in vivo
Quick Facts
- Class
- Bioregulator Peptide
- Tier
- D
- Evidence
- Preliminary
- Safety
- Limited Data
- Updated
- May 2026
- Citations
- 8PubMed
Also known as
Tags
Peptide Families
Related Goals
Conditions Discussed
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.